HistoIndex partners with A*STAR to advance early-stage development of pipeline therapies for fibrotic diseases in Singapore
Singapore, Oct. 19 -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterisation of therapeutic candidates for various fibrotic diseases, including cancer-associated fibrosis.
The partnership will bring together A*STAR's scientific expertise and therapeutic development capabilities with HistoIndex's proprietary imaging technology and AI-powered fully quantitative tissue analysis.
By providing objective, sensitive and accurate measures of fibrosis and treatment response, HistoIndex's platform will support ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.